| scholarly article | Q13442814 |
| P50 | author | Junxia Min | Q43178391 |
| P2093 | author name string | Frank Stegmeier | |
| Yi Yang | |||
| Qianhe Zhou | |||
| Michael R Schlabach | |||
| Daniel Rakiec | |||
| David Ruddy | |||
| Adnan Derti | |||
| HoMan Chan | |||
| Iris Kao | |||
| Michelle Lira | |||
| Veronica Gibaja | |||
| P2860 | cites work | Drug development: Raise standards for preclinical cancer research | Q22348097 |
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1949-1958 | |
| P577 | publication date | 2015-03-18 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | A chemical genetics approach for the functional assessment of novel cancer genes | |
| P478 | volume | 75 |
| Q90700699 | Altered RNA Processing in Cancer Pathogenesis and Therapy |
| Q64106877 | Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability |
| Q88912942 | Alternative splicing and cancer metastasis: prognostic and therapeutic applications |
| Q60915920 | CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics |
| Q33772342 | CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery |
| Q38614582 | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer |
| Q38972458 | Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. |
| Q38712211 | Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1. |
| Q49850933 | H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. |
| Q92497936 | Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation |
| Q33640195 | How do messenger RNA splicing alterations drive myelodysplasia? |
| Q49363972 | Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins |
| Q92114066 | Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies |
| Q41091296 | Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. |
| Q37391660 | RNA splicing factors as oncoproteins and tumour suppressors |
| Q35913831 | Selectable one-step PCR-mediated integration of a degron for rapid depletion of endogenous human proteins |
| Q55353370 | Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. |
| Q39217354 | Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures |
| Q57106833 | Splicing dysregulation as a driver of breast cancer |
| Q63649314 | Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations |
| Q91865401 | Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia |
| Q50209871 | The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. |
| Q99241129 | The biological function and clinical significance of SF3B1 mutations in cancer |
| Q52340959 | The dTAG system for immediate and target-specific protein degradation. |
| Q38948363 | Therapeutic targeting of splicing in cancer |
| Q36342704 | Using a biologically annotated library to analyze the anticancer mechanism of serine palmitoyl transferase (SPT) inhibitors. |
| Q42338844 | Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma |
| Q58570841 | Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer |
| Q36173000 | Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival |
Search more.